SocialPicks Monitor new  |    Stock Idea Community
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 XOMA Ltd.  (XOMA) Trade Now »     Rate XOMA  -  Discuss XOMA  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
84.5%
Top:
0.0%
Rate XOMA:



XOMA Analysis & Videos »


XOMA: Bull or Bear?

XOMA Making the Right Moves Graphic_rating_buy XOMA
-59.33%
in 192 days
We believe Xoma's antibody discovery platform is starting to show signs of paying off, as both -052 and -629 could prove to be significant products.
By  Zacks.com   (-29.25%  risk: conservative)  05/13/08 Comment


Royalties to Increase Graphic_rating_buy XOMA
Astukphoto
19%
 -68.40%
in 275 days
Sales of all products that Xoma recieves a royalty on have been reported by collaboration partners. We are expected total royalty revenues for the fourth quarter 2007 of $4.9 million. This is up slightly from our previous forecast of $4.7 million thanks to stronger international sales of both Raptiva and Lucentis. Xoma is expected to report fourth quarter
results on March 11, 2008. We are forecasting total revenues for the quarter of $13.2 million (consensus is $12.1 million) and EPS of -$0.10 (consensus is -$0.12).
Xoma remains significantly under-valued in our view. We maintain ou...
By  Armin Stuk   (-44.02%  risk: conservative)  02/20/08 Comment


Bullish on XOMA ... Graphic_rating_buy XOMA
22%
 -17.53%
in 21 days
(closed on 01/14/08)
2008 potential double. Earnings due out soon and will be better than expected. Momentum stock and great appreciation in 2008
By  JIMMY T   (-26.98%  risk: conservative)  12/24/07 Comment


Get free stock alert for XOMA:
Your Email Address:


Low float, big news, big industry Graphic_rating_buy XOMA
N/A
 -60.65%
in 711 days
Xoma, Novartis: Positive results from Phase I HCD122 trial
10:54a ET December 11, 2006 (Marketwatch)

SAN FRANCISCO (MarketWatch) -- Xoma Ltd. and Novartis AG on Monday presented positive results from their pre-clinical and preliminary Phase 1 clinical trial of the experimental drug HCD122. The drug candidate is an anti-CD-40 monoclonal antibody designed to treat patients with relapsed and refractory multiple myeloma and chronic lymphocytic leukemia. The development of HCD122 began in 2004 as part of Xoma's collaboration with Chiron Corp., which Novartis acquired earlier this year. Chiro

...
By  clam61   (-61.57%  risk: aggressive)  12/11/06 Comment





People Bullish on XOMA

JIMMY T
Associate
22%
6 mos ago

Zacks.com
Tracked Blogger
29%
6 mos ago

yosef
Analyst
N/A
7 mos ago

Nathan D
Analyst
N/A
8 mos ago

Astukphoto
Armin Stuk
Sr. Associate
19%
9 mos ago


People Bearish on XOMA

Canada
Yannis Maarten
Associate
84%
3 mos ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 29.65 +61.65% 160
2 Gerald Greene 21.24 +48.89% 50
3 The Big Bear 19.00 +49.44% 205
4 krprasad 17.77 +19.60% 4
5 David Young 15.63 +16.16% 6


POPULAR STOCKS
Symbol Company Name Sentiment
AMZN Amazoncom Inc
GOOG Google Inc
MA MasterCard Inc
CSCO Cisco Systems Inc
GLD streetTRACKS Gold
IBM International Business Machines Corp

TODAY'S HEADLINES

TODAY'S TOP PICKS

 


StreetInsider.com on XOMA


Discussion Wall + Add  
shohmann2ucr   (+0.00%)
hold - I heard of this stock from my boss at work. He has had this stock for years. In fact, he said he has had XOMA for more than 10 or 15 years. He holds st
+   0 replies


More Resources

Graphic_arrow1 About XOMA Ltd. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch